Hydroxychloroquine and the Risk of Sudden Cardiac Death
Madeleine G. Yemc, BS, Melissa R. Laughter, MD, PhD, Jeremy Hugh, MD, Elizabeth Wallace, MD
Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Introduction

- Hydroxychloroquine (HCQ) is an antimalarial drug that is widely utilized in dermatology to treat autoimmune disorders and connective tissue diseases.
- QT interval prolongation is a well-documented adverse event associated with HCQ.
- Drug-induced QTc prolongation can lead to torsades de pointes and sudden cardiac death in certain individuals.
- It remains unclear if QTc prolongation from HCQ is associated with an increased risk of sudden cardiac death, particularly in the context of long-term, dermatologic usage of HCQ.
- Multiple studies have evaluated the relationship between short-term HCQ usage and sudden cardiac death in hospitalized COVID-19 patients with conflicting results.
- Only one study to date has evaluated the relationship between long-term HCQ usage and sudden cardiac death, finding a statistically significant increased risk of sudden cardiac death among patients currently taking HCQ.

Hypothesis & Aim

Hypothesis: There is no meaningful association between hydroxychloroquine and sudden cardiac death when the medication is used to treat dermatologic conditions.

Aim: To investigate the relationship, if any, between hydroxychloroquine and sudden cardiac death by comparing the relative risk of sudden cardiac death among individuals taking hydroxychloroquine for a dermatologic disorder to that of a matched control population of non-hydroxychloroquine users.

Methods

- Retrospective cohort study of patients with lichen planopilaris (LPP), granuloma annulare (GA), or frontal fibrosing alopecia (FFA) seen in UCHEalth Dermatology Outpatient Clinics from 1/1/2000 – 1/1/2021
- Study Design: Total population n = ?
  - Dx of LPP, GA, or FFA
  - Age 30-74 y/o
  - Insured
  - Follow-up with physician within 1 year of starting medication
  - HCQ
  - Control population n = ?
  - Other systemic/topical medications

Study Period: Date of the patient’s first-follow up appointment until death of the patient, termination of insurance enrollment, or the date on which inclusion criteria were no longer met

Statistical Analysis:
- Relative risk of sudden cardiac death will be estimated with the incidence-rate ratio, as calculated from Poisson regression models.
- Relative risk may be stratified by dose of HCQ if sufficient data available.

Results
- Results are pending.
- Due to delays in the data acquisition process, we are currently still in the process of obtaining our control data

Discussion and Conclusion

- The results of this study will help elucidate the relationship, if any, between hydroxychloroquine and sudden cardiac death, when used to treat dermatologic conditions.
- These findings may help guide future dermatology practices surrounding cardiac disease screening and/or monitoring for persons taking hydroxychloroquine.

Limitations

- Population size and the need to use sudden cardiac death as an endpoint since ECGs are not routinely collected in the population being studied may be limitations.

Acknowledgements

- We thank the Colorado Multiple Institutional Review Board for approving access to data (protocol number 20-1760).
- We thank Dr. Elizabeth Wallace and Dr. Jeremy Hugh for providing mentorship throughout this project.
- We thank Dr. Melissa R. Laughter for developing the data analysis plan.
- We thank Health Data Compass for assistance with data collection.

References